{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:59:07Z","timestamp":1792241947545,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116323","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T03:14:34Z","timestamp":1710731674000},"page":"116323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation"],"prefix":"10.1016","volume":"269","author":[{"given":"Xiaodong","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yameng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-9034","authenticated-orcid":false,"given":"Ning","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116323_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111678","article-title":"Recent advances on FXR-targeting therapeutics","volume":"552","author":"Panzitt","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116323_bib2","first-page":"1403","article-title":"Farnesoid X receptor: a potential therapeutic target in multiple organs","volume":"35","author":"Zhang","year":"2020","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ejmech.2024.116323_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbadis.2017.10.003","article-title":"Farnesoid X receptor: a \"homeostat\" for hepatic nutrient metabolism","volume":"1864","author":"Massafra","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2024.116323_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2024.116323_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tem.2011.07.002","article-title":"Hepatic FXR: key regulator of whole-body energy metabolism","volume":"22","author":"Teodoro","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ejmech.2024.116323_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116323_bib7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1210\/me.2010-0014","article-title":"Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner","volume":"24","author":"Li","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116323_bib8","doi-asserted-by":"crossref","first-page":"G798","DOI":"10.1152\/ajpgi.00319.2004","article-title":"Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver","volume":"289","author":"Zollner","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ejmech.2024.116323_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1053\/jhep.2002.31724","article-title":"Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump","volume":"35","author":"Plass","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116323_bib10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/toxsci\/kfu151","article-title":"Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures","volume":"141","author":"Liu","year":"2014","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2024.116323_bib11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","article-title":"Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice","volume":"56","author":"Kong","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2024.116323_bib12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2024.116323_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(00)00050-2","article-title":"Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors","volume":"6","author":"Lu","year":"2000","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2024.116323_bib14","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1194\/jlr.M300182-JLR200","article-title":"FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits","volume":"44","author":"Xu","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116323_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2024.116323_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2024.116323_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lab.2006.03.009","article-title":"Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans","volume":"148","author":"Wang","year":"2006","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejmech.2024.116323_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000199204","article-title":"Increase in serum total cholesterol and low-density lipoprotein cholesterol by high-dose chenodeoxycholic acid in patients with radiolucent gallstones significantly reversed during preventive low dose after gallstone dissolution","volume":"31","author":"Perez-Aguilar","year":"1985","journal-title":"Digestion"},{"key":"10.1016\/j.ejmech.2024.116323_bib19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1194\/jlr.M600120-JLR200","article-title":"Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia","volume":"47","author":"Ratliff","year":"2006","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2024.116323_bib20","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1021\/acs.jmedchem.1c01017","article-title":"Recent advances in the medicinal chemistry of farnesoid X receptor","volume":"64","author":"Fang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116323_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/0253-7613.91868","article-title":"Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone","volume":"44","author":"Kumar","year":"2012","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116323_bib23","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1210\/mend.16.7.0894","article-title":"The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor","volume":"16","author":"Wu","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.116323_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/1570180815666171226150403","article-title":"Synthesis and biological evaluation of N-(5-(2,5-dimethyl-phenoxy)-2,2dimethylpentyl)-benzamide derivatives as novel farnesoid X receptor (FXR) antagonist","volume":"15","author":"Nian","year":"2018","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2024.116323_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.metabol.2018.03.016","article-title":"HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1\u03b1 promoter","volume":"85","author":"Xu","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2024.116323_bib26","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.bmc.2007.01.046","article-title":"Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist","volume":"15","author":"Kainuma","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib27","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1021\/jm3002718","article-title":"Discovery and optimization of 1,3,4-Trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists","volume":"55","author":"Huang","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2013.10.048","article-title":"Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates","volume":"723","author":"Amano","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116323_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejmech.2017.02.037","article-title":"Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists","volume":"129","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib30","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.bmc.2019.04.029","article-title":"Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: comprehensive understanding of structure-activity relationship of FXR antagonists","volume":"27","author":"Teno","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acsmedchemlett.8b00534","article-title":"Investigation around the oxadiazole core in the discovery of a new chemotype of potent and selective FXR antagonists","volume":"10","author":"Festa","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116323_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/acsmedchemlett.0c00647","article-title":"A new FXR ligand chemotype with agonist\/antagonist switch","volume":"12","author":"Helmst\u00e4dter","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116323_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.11.027","article-title":"5 Alpha-bile alcohols function as farnesoid X receptor antagonists","volume":"339","author":"Nishimaki-Mogami","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2024.116323_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116323_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.cmet.2020.11.017","article-title":"Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism","volume":"33","author":"Zheng","year":"2021","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2024.116323_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"Lyu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116323_bib37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","article-title":"An open-source drug discovery platform enables ultra-large virtual screens","volume":"580","author":"Gorgulla","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116323_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2027-0","article-title":"Virtual discovery of melatonin receptor ligands to modulate circadian rhythms","volume":"579","author":"Stein","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116323_bib39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the sigma(2) receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116323_bib40","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1021\/ci500062f","article-title":"An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to GPCRs","volume":"54","author":"Xia","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.116323_bib41","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1021\/jm3002718","article-title":"Discovery and optimization of 1,3,4-Trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists","volume":"55","author":"Huang","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11030-018-9843-2","article-title":"Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists","volume":"23","author":"Nian","year":"2018","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2024.116323_bib43","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","article-title":"Discovery of highly potent and selective thyroid hormone receptor beta agonists for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib44","series-title":"LigPrep, Version 2.3; Schrodinger","year":"2015"},{"key":"10.1016\/j.ejmech.2024.116323_bib45","series-title":"Epic, Version 3.2; Schrodinger","year":"2015"},{"key":"10.1016\/j.ejmech.2024.116323_bib46","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib47","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112445","article-title":"Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors","volume":"201","author":"Dou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114508","article-title":"Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease","volume":"238","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116323_bib50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2024.116323_bib51","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1021\/jacsau.2c00600","article-title":"Biomimetic total synthesis and the biological evaluation of natural product (\u2212)-Fargesone A as a novel FXR agonist","volume":"2","author":"Guo","year":"2022","journal-title":"JACS Au"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T17:26:54Z","timestamp":1712942814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S0223523424002034"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116323","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116323"}}